Competitor News, Synthetic Data

MIT STARTUP INTRODUCES SYNTHETIC DATA METRIC TO EVALUATE SYNTHETIC DATA

The Synthetic Data Metrics help compare individual aspects of synthetic data vis-à-vis real data AI laboratory DataCebo, an MIT startup introducesSynthetic DataMetrics, a new tool, for companies to compare synthetic data to real-world data sets. Synthetic Data Metrics is an open-source Python library that defines metrics for synthetic data and works across different types of tabular data for evaluating…

Competitor News, Product Updates

Ciox Health creates platform for providers to offer patients immediate access to their medical records

Ciox’s digital electronic medical record (EMR) connections combined with services-based retrieval of other electronic data ensure compliance with the 21st Century Cure Act deadline ALPHARETTA, Ga., Oct. 7, 2022 /PRNewswire/ — As the industry leader in compliant exchange of medical data, Ciox, a Datavant company, partners with health systems to efficiently deliver…

Academic, Oncology, Partner and Collaborator News

New Center for Experimental Therapeutics in Cancer advances promising treatments

Center will serve as a hub for commercialization of promising cancer therapies UC Davis Comprehensive Cancer Center has launched a Center for Experimental Therapeutics in Cancer to accelerate promising cancer therapies from the lab to the bedside. The goal is to facilitate the commercialization of promising drugs emerging from UC Davis…

Collaborations, Partner and Collaborator News

Palantir Selected by Army Materiel Command to Support Prognostic and Predictive Maintenance Requirements

DENVER, Oct. 6, 2022 /PRNewswire/ — Palantir Technologies Inc. (NYSE: PLTR) today announced that it was selected by the U.S. Army Materiel Command (AMC) to support its prognostic and predictive maintenance and supply chain optimization efforts. AMC will utilize Palantir’s software to support logistics in contested environments, improve equipment reliability, and advance supply…

Collaborations, Competitor News, Data Partnership, Oncology, Pharma

Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics

October 06, 2022 10:30 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with Kartos Therapeutics, a clinical stage biopharmaceutical company, in support of its ongoing Phase II study of navtemadlin (KRT-232). Tempus’ CDx…

Events, Industry News, Marketing

The Strategic and Scientific Imperative for Prospectively Generated Real-World Evidence, Upcoming Webinar Hosted by Xtalks

TORONTO (PRWEB) OCTOBER 06, 2022 The data characterizing the real-world clinical, economic and humanistic impact of innovative medical products are increasingly used across the broad spectrum of clinical and commercial development to support both regulatory approval and market access (with the former being a relatively new phenomenon since implementation of the…

Collaborations, Competitor News, Data Partnership

Mutations of SPOP (mtSPOP) as Treatment Selection Biomarkers

Oct 5, 2022 For patients with mCSPC, the current standard of treatment is to intensify androgen deprivation therapy (ADT) with docetaxel or androgen receptor axis-targeted therapy (ARAT: abiraterone, apalutamide, enzalutamide). But there aren’t enough indicators to help with therapy decision-making. Researchers had previously demonstrated that ADT enhanced the survival results…